BioSpace News Archive

Jubilant Radiopharma, the Radiopharmaceutical Division of Jubilant Pharma Ltd, announced today that the company received approval from Health Canada for Drax Exametazine® (Kit for the Preparation of Tc99m Exametazime for leukocyte labeling).

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the opening of its new corporate headquarters, located at 800 Saginaw Drive in Redwood City, CA

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2019 on Thursday, February 6, 2020, before the U.S. financial markets open.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2019 results after the financial markets close on Monday, February 24, 2020.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) granted the Company’s motion to vacate and remand the Patent Trial and Appeal Board (PTAB) decision to invalidate U.S. Patent No. 9,249,149 (’149 patent).

AIDS Foundation Houston Inc., a nonprofit dedicated to ending the HIV epidemic and supporting those affected by HIV, announces a new partnership with MISTR to provide convenient access to PrEP, or pre-exposure prophylaxis medication.

Invacare Corporation (NYSE: IVC) (“Invacare” or the “company”) announces that it will release its financial results for the fourth quarter and year ended December 31, 2019, on Monday, February 10, 2020 at 6:00 a.m. ET, followed by a live conference call and webcast to discuss these financial results at 8:30 AM ET.

The rare genetic disease CDKL5 Deficiency Disorder (CDD) has been designated with a new disease code in the International Classification of Diseases (ICD), the medical classification list from the World Health Organization (WHO).

CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, announces it has completed all payment obligations for the June 2019 acquisition of New Jersey Alternative Medicine (“NJAM”)

Merit Medical Systems, Inc. confirmed that it has received notice from Starboard Value LP that it has nominated seven individuals to stand for election as directors at Merit’s 2020 Annual Meeting of Shareholders.